Intravenous versus subcutaneous immunoglobulin

Affiliations

¹ Department of Neurology, King George Medical University, Lucknow 226003, Uttar Pradesh, India. Electronic address: raviuniyal@kgmcindia.edu.
² Department of Neurology, King George Medical University, Lucknow 226003, Uttar Pradesh, India.

Comment

Ravi Uniyal et al. Lancet Neurol. 2018 May.

. 2018 May;17(5):393.

doi: 10.1016/S1474-4422(18)30106-6.

¹ Department of Neurology, King George Medical University, Lucknow 226003, Uttar Pradesh, India. Electronic address: raviuniyal@kgmcindia.edu.
² Department of Neurology, King George Medical University, Lucknow 226003, Uttar Pradesh, India.

No abstract available

Comment in

Intravenous versus subcutaneous immunoglobulin - Authors' reply.
van Schaik IN, Mielke O; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 May;17(5):393-394. doi: 10.1016/S1474-4422(18)30109-1. Lancet Neurol. 2018. PMID: 29656738 No abstract available.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Clinical Trial.